Another randomized control study showed that an FMT from a thin and healthy donor to NAFLD patients reduced intestinal permeability, but could not improve insulin resistance and hepatic proton density fat fraction [83]. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.